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Radiolabeling cidofovir with technetium-99m (99mTc-CDV) is an innovative procedure that enables 
real-time monitoring of the drug. Essays were performed in vitro, showing high radiolabel stability 
within 24 h. Blood clearance, biodistribution studies, and scintigraphic images were performed in 
healthy mice in order to evaluate the profile of the drug in vivo. 99mTc-CDV showed biphasic blood 
circulation time and significant kidney uptake, indicating that 99mTc-CDV is preferentially eliminated 
by the renal route. Bones also showed important uptake throughout the experiment. In summary, 
cidofovir was successfully labeled with technetium-99m and might be used in further studies to track 
the drug.
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INTRODUCTION
Cidofovir (CDV) is a cytosine nucleotide analogue 
with broad-spectrum anti-DNA virus activity, including 
human cytomegalovirus (HCMV), which was first 
reported in 1986 and approved by the US Food and 
Drug Administration (FDA), under the trade name 
of Vistide®, for the systemic treatment of HCMV 
retinitis in people with acquired immunodeficiency 
syndrome (Jackowska, 2018; Broekema, Dikkers, 2008; 
Andrei, Snoeck, 2010). Currently, CDV has been used 
to treat some viral infections, but mainly recurrent 
respiratory papillomatosis (RRP), which is a chronic 
disease caused by Human Papilloma Virus (HPV) 
and affects mainly children and teenagers. The use of 
antivirals as adjuvants on the treatment of RRP has been 
shown to be more effective in the control of laryngeal 
lesions, with cidofovir (CDV) being the most used off-
label drug currently used (Tran, Galt, Bashirzadeh, 
2018; Rasmussen et al., 2017; Carifi et al., 2015). Its 
mechanism of action is based on the inhibition of the 
viral DNA polymerase, followed by incorporation into 
the growing DNA chain, resulting in low efficiency of 
DNA transcription (Fusconi et al., 2014). Although few 
side effects of CDV have been reported, some of them 
are described as rash, headache, local inflammation, and 
potential nephrotoxicity; in animal studies, concerns 
have been raised about carcinogenicity (Coomes, 2018; 
Sahota et al., 2011).
Labeling molecules with radioisotopes, such as 
technetium-99m (99mTc), enables us to determine, 
in real-time, the radiometal complex biodistribution 
(Snehalatha et al., 2008). This method is an important 
tool in studying pharmacokinetics, once it permits 
direct visualization and quantification of the drug. 99mTc 
is the commonly used radioisotope due to its physical 
and chemical characteristics, such as low energy (140 
KeV), large availability in nuclear medicine laboratories 
and inexpensive isotope cost (Fernandes et al., 2015; De 
Barros et al., 2013; Yang et al., 2003).
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FIGURE 1 - Chemical structure of cidofovir.
Technetium-99m is obtained from the Molybdenum 
generator as sodium pertechnetate (99mTc-NaTcO4), and 
the ion 99mTcO4- is chemically nonreactive. Therefore, 
prior reduction of 99mTc from the 7+ state to a lower 
oxidation state, most commonly to 4+, is required, 
and among various reducing agents, stannous chloride 
(SnCl2.H2O) is often the chosen one in preparations of 
99mTc-labeled compounds. The reactive species usually 
combine with chelating agents, so that the chelating 
agent donates lone pairs of electrons to form coordinate 
covalent bonds (Papagiannopoulou, 2017). CDV has 
several functional groups, such as –NH2, -O-, -POOH 
(Figure 1), which are able to donate pairs of electrons 
and form complexes with 99mTc. Unlike in nucleoside 
phosphates, in acyclic nucleoside phosphonates, such 
as CDV, the phosphonate group is already attached 
to the nucleoside analog, resulting in the formation of 
a phosphonomethyl ether (-P-C-O-), which confers 
resistance to esterases (Andrei & Snoeck, 2010). This 
fact is especially important to keep the drug molecule 
integrity since phosphonates are very common chelator 
to 99mTc (Saeed et al., 2017). Thus, CDV might be a 
potential target to electron-deficient radiometals, such 
as 99mTc, producing a stable complex that will allow 
tracking the in vivo behavior of CDV.
Even though there are some pharmacokinetics 
studies of CDV already published in the literature, 
radiolabeling CDV with 99mTc provides a new tool for 
understanding this drug’s behavior in the body, as well 
as obtaining a general overview of its biodistribution in 
real time by scintigraphy. Developing a bioanalytical 
HPLC method to quantify CDV in vivo can be quite 
challenging, especially when the purpose of the study 
is to screen the drug after intravenous administration, 
and not only in a specific organ or tissue, which justifies 
the development of a radiotracer capable of monitoring 
CDV to better understand its pharmacokinetic profile.
Therefore, the aim of this study was to label CDV 
with 99mTc and evaluate its in vitro stability. In addition, 
biodistribution studies and scintigraphic imaging were 




Cidofovir hydrate (CDV), >98.0%, was purchased 
from Sigma-Aldrich (São Paulo, Brazil). 99mTc was 
obtained from an alumina-based 99Mo/99mTc generator. 
All reagents (analytical grade), including SnCl2.2H2O 
98.0%, were purchased from Sigma-Aldrich (São Paulo, 
Brazil). Healthy 4-6-week-old female Swiss mice, 20g, 
were acquired from CEBIO-UFMG (Belo Horizonte, 
Brazil). All animal studies were approved by the local 
Ethics Committee for Animal Experiments (CEUA/
UFMG), under protocol number 184/2017.
In vitro studies
Radiolabeling procedure
CDV (1.0 mg) was dissolved in 300 µL of NaCl 
0.9% (w/v). An aliquot of 100 µL of a SnCl2.2H2O 
98.0% solution in HCl 0.25 M was added and the pH was 
adjusted to 7.0 with a 1M NaOH solution. The vacuum 
was applied in the vials and an aliquot of 0.1 mL of 
Na99mTcO4 (37 MBq) was added. The final solution was 
kept at room temperature for 15 minutes to complete the 
radiolabeling procedure.
Radiochemical purity evaluation
The radiolabeled efficiencies were analyzed by 
ascending thin layer chromatography (TLC) on silica 
gel strips (TLC-SG; Merck, Darmstadt, Germany) 
as the stationary phase and acetone as the mobile 
phase. In this system, free 99mTcO4- showed Rf = 1, 
while 99mTcO2 99mTc-CDV showed Rf = 0. The amount 
of free 99mTcO4- was determined by measuring the 
radioactivity of the strips in a gamma counter (Wallac 
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Wizard 1470-020 Gamma Counter; PerkinElmer Inc., 
Waltham, Massachusetts, USA). The solution was 
purified from 99mTcO2 using a 0.22 µm syringe filter 
(6). The analysis was performed in triplicate. The 
HPLC analysis was conducted using a previously 
validated method for specificity, linearity, precision, 
and accuracy, adapted from Santoyo et al. (2002), using 
an Agilent® with a DAD detector at a wavelength of 
274 nm. HPLC mobile phase consisted of a mixture 
of a 1,5mM tetrabutylammonium phosphate and a 3,5 
mM monobasic sodium phosphate buffer solution with 
acetonitrile 99.9% (97:3 v/v), pH=6.0. A Purospher® 
C-18 column (5.0 µm, 4.6 mm x 250 mm) was used 
at a rate of 1.0 mL/min, under isocratic elution, with 
an injection volume of 10 µL. Samples were collected 
every 10 seconds, in different tubes, for 25 min, and 
radiation was measured in a gamma counter.
In vitro stability
TLC-SG was used to estimate the stability 
99mTc-CDV in the presence of saline 0.9% (w/v) and 
mouse plasma. To determine the saline stability, the 
labeled solution was kept at room temperature and the 
radiochemical stability was determined from samples 
taken at 1, 2, 4, 6 and 24 h after incubation. Plasma 
stability was assessed by incubating a volume of 90 µL 
of the 99mTc-CDV solution, under agitation, at 37°C with 
1.0 mL of fresh mouse plasma. EDTA was used as an 
anticoagulant. Radiochemical stability was determined 
from samples taken at 1, 2, 4, 6 and 24 h after incubation. 
Both stability analyzes were performed in triplicate.
Partition coefficient
Aliquots of 0.1 mL of the 99mTc-CDV (0.37 MBq) 
were added to tubes containing 2.0 mL of n-octanol/
water (1:1). The tubes were submitted to vigorous 
stir for 5 min. After phase separation, aliquots of 0.5 
mL from each phase were collected and radioactivity 
was measured in a gamma counter. The analysis was 
performed in triplicate. Partition coefficient was 
determined according to the equation:
Partition coefficient = log
organic phase (cpm) x 100
aquous phase (cpm)
Plasma protein binding
Plasma protein binding profile was estimated by 
the protein precipitation method. An aliquot of 45 µL of 
99mTc-CDV was added to 3 different vials containing 500 
µL of fresh mouse plasma and incubated at 37 °C, under 
agitation. EDTA 99.9% was used as an anticoagulant. At 
30 min, 1 and 4h after incubation, an aliquot of 1.5 mL 
of acetonitrile was added to each vial for plasma protein 
precipitation. Samples were centrifuged at 5000xg for 
3 min, and the radioactivity of supernatant and pellet 
was measured in a gamma counter. The analysis was 
performed in triplicate. Percent of protein binding was 
calculated according to the equation:





99mTc-CDV was administrated to each mouse (n=7), 
previously anesthetized with a mixture of xylazine (15 
mg/kg) and ketamine (80 mg/kg), through the tail vein, 
and a small incision was made in the distal tail to facilitate 
rapid and reliable blood collection. Blood samples (~20 µL 
each) were collected at 1, 5, 10, 15, 30, 45, 60, 90, 120 and 
240 min after administration. Each sample was weighed 
and the radioactivity was measured with an automatic 
scintillation counter. The percentage of injected activity 
per gram (%ID/g) and its mean ± SD in each sample 
were determined, and the data were plotted as a function 
of time. Blood clearance analysis was performed using 
GraphPad PRISM, version 5.00 software (GraphPad 
Softwar Inc., La Jolla, California, USA).
Ex vivo biodistribution
Aliquots of 3.7 MBq of 99mTc-CDV were injected 
intravenously into the tail vein of Swiss mice (n=7). At 
1 and 4 h after injection, mice were anesthetized with 
a mixture of xylazine (15 mg/kg) and ketamine (80 
mg/kg). Blood, spleen, kidneys, stomach, lungs, heart, 
intestines, muscle, bone, thyroid, brain and liver were 
removed and placed in pre-weighed plastic test tubes. The 
radioactivity was measured by an automatic scintillation 
counter. A standard dose containing the same injected 
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amount was counted simultaneously in a separated tube, 
which was defined as 100% radioactivity. The results 
were expressed as the percentage of injected dose per 
gram of tissue (%ID/g).
Scintigraphic images
Aliquots of 3.7 MBq of 99mTc-CDV were injected 
intravenously into the tail vein of Swiss mice (n=7). 
Mice were anesthetized and then horizontally placed 
under the collimator of a gamma camera (Mediso, 
Budapest, Hungary) coupled with a low-energy high-
resolution collimator. Images were acquired at 1 and 4 
h after injection using a 256x256x16 matrix size, with 
a 20% energy window set at 140 Kev for a period of 
300s each.
Statistical analysis
All data are expressed as mean ± SD and they were 
analyzed by GraphPad PRISM, version 5.0 software 
(GraphPad Software Inc.). 
RESULTS
Radiochemical purity and in vitro stability
99mTc-CDV was efficiently labeled with technetium-
99m, showing, after filtration in a 0.22 µm sterile filter, 
radiochemical yields of 99.3 ± 0.2% (n=3). Results 
obtained by HPLC analysis corroborate with TLC data, 
as demonstrated in Figure 2. The radiation peak (Figure 
2A) occurs at almost the same retention time of 99mTc-
CDV obtained in the chromatogram (Figure 2B), which 
indicates a single 99mTc-labeled species, indicating 
similar radiochemical yields than those obtained by 
TLC. Radiochemical stability was also performed at 
1, 2, 4, 6 and 24 h post-incubation in saline, at room 
temperature, or in mouse plasma, at 37 °C. The complex 
99mTc-CDV remains stable, in both media, even after 
long periods, as shown in Figure 3.
Partition coefficient
The partition coefficient of 99mTc-CDV was 
determined by the ratio between n-octanol and water, 
and the log P found for 99mTc-CDV was in the hydrophilic 
range (log P = -1.39 ± 1.9) (n=3).
Plasma protein binding
High plasma protein binding was observed for 
99mTc-CDV. At 30 min post-incubation, 45.7 ± 1.5% of 
99mTc-CDV was bound to plasma protein. After 1 h, 90.1 
± 0.8% of binding was reached, and the level of protein 
binding was kept at 91.1 ± 1.0% after 4 h (n=3).
Animal studies
Blood clearance
The injection of 99mTc-CDV through the tail vein of 
the mice showed a long blood clearance of the complex, 
with a biphasic half-life profile. Figure 4 exhibits the 
distribution half-life of 2.3 min and the elimination half-
life of 227.1 min and an area under the curve of 2850% 
ID/min (n=7).
Ex vivo biodistribution
Figure 5 shows the biodistribution of 99mTc-CDV 
at 1 and 4h after intravenous administration in healthy 
mice. At both times, maximum uptake was observed in 
the kidneys, followed by the bones. Moreover, important 
uptake was also observed in the small intestine and 
the liver, indicating that intestinal route contributes to 
the excretion of 99mTc-CDV. No significant uptake was 
observed in other organs (n=7).
Scintigraphic images
Scintigraphic imaging exhibited a similar profile 
to the one presented by the biodistribution studies, as 
shown in Figure 6. The image of 1h shows a strong 
signal in the abdominal area, most likely as a result of 
the high uptake by the kidneys, small intestine, and liver. 
At the time of 4 h, signal strength decreases, due to drug 
clearance. In addition, in both images, it is noticeable 
the signal emitted by bone uptake (arrows) (n=7).
DISCUSSION
Cidofovir is a cytidine analog that suppresses 
viral replication by the selective inhibition of DNA 
synthesis, being active against all kinds of herpesvirus, 
cytomegalovirus, adenovirus, polyomavirus and 
human papillomavirus (Sala, Suriol, Montero, 2017). 
Even though CDV is not licensed for this indication, 
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FIGURE 2 - Reverse phase HPLC chromatogram (a) and radiochromatogram (b) of 99mTc-CDV.
FIGURE 3 - In-vitro stability of 99mTc-CDV as a function of time in the presence of saline, at room temperature, and in the 
presence of mouse plasma, at 37 °C (n=3).
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FIGURE 4 - Blood clearance of 99mTc-CDV in healthy female SWISS mice. All data are the mean percentage (n=7) of the 
injected dose of 99mTc-CDV per gram of blood, ±SD of the mean.
FIGURE 5 - Biodistribution profile of 99mTc-CDV following intravenous tail-vein administration in healthy female SWISS mice. 
All data are the mean percentage (n=7) of the injected dose of 99mTc-CDV per gram of tissue ± SD of the mean.
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it is currently the mainstay of antiviral therapy for 
adenovirus (Vora, Brothers, Englund, 2017). Indeed, 
there are several case series showing the efficacy of CDV 
in adenovirus pneumonia (Lee et al., 2017). It is known 
that intralesional CDV may help control papilloma 
regrowth and reduce disease severity in children with 
recurrent respiratory papillomatosis, as well (Goon 
et al., 2008).
The diverse chemistry of 99mTc has led to the 
development of numerous 99mTc radiopharmaceuticals 
suitable for various diagnostic procedures, since they 
will distribute, after being systemically administrated, 
and accumulate in the organ or tissue of interest 
according to their design (Papagiannopoulou, 2017). In 
this regard, considering there is still no published study 
on the radiolabeling of CDV, the aim of this study was 
to develop a radiotracer with 99mTc in order to further 
evaluate the in vivo biodistribution of CDV.
After being purified from 99mTcO2, the stability of 
the complex 99mTc-CDV was evaluated and it showed 
stability over 90% in both saline and plasma, at all 
evaluated times. These results guarantee that, during 
all time of analysis, monitoring the behavior of 99mTc 
reflects the behavior of CDV itself.
Blood clearance data show that blood levels of 99mTc-
CDV decays in a biphasic manner, showing a slow half-
life of 227.1 min. These results are in agreement with 
a previously published study, in which CDV showed a 
slow half-life of 5.8 h (Brown et al., 2015). The relatively 
long half-life of the 99mTc-CDV, a small and hydrophilic 
complex, might explain the high plasma protein binding 
for 99mTc-CDV, with a maximum of 88.9±0.0% at 1 h 
post-incubation. log P of -1.39 ± 1.9 found for 99mTc-
CDV also reflects the high hydrophilicity of the complex 
due to its polar character. It is worth mentioning, that, 
to the best of knowledge, this is the first report of 
radiolabeled CDV. The use of radiolabeled molecules is 
an exquisite strategy to track in vivo, at real time, the 
desired compound providing quantitative information 
about tissue distribution. 
In this sense, we also performed biodistribution 
studies in healthy mice to predict the behavior of CDV 
after being administrated systemically. At 1 and 4 h 
post-administration, maximum uptake was observed in 
the kidneys, as expected, due to the high hydrophilicity 
of CDV, as demonstrated by its partition coefficient. In 
addition, this profile indicates a main renal excretion 
and might be related to the high nephrotoxicity of 
CDV, as previously described in the literature (Mareri 
et al., 2016). Furthermore, a high uptake was found in 
the bones. Bones are composed of various inorganic 
ions, mainly calcium and phosphate and, therefore, 
they show an affinity for compounds that present these 
ions. Even though CDV presents a phosphonate group 
instead of a phosphate one, both are very similar, which 
explains the bone uptake, as demonstrated before with 
FIGURE 6 - Scintigraphic images obtained at 1 (a) and 4 (b) h after intravenous injection of 99mTc-CDV into healthy mice (n=7). 
The arrows indicate bone uptake.
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MDP (methoxy diphosphonate), a radiopharmaceutical 
used to diagnose bone metastasis (Saeed et al., 2017). 
It is important to mention that small intestine and liver 
showed moderate uptake indicating the contribution of 
the intestinal route. Scintigraphic imaging of the mice 
corroborates with the biodistribution data found.
These results pose new perspectives to monitor 
CDV in vivo in real time in different experimental 
models to better understand drug behavior. Moreover, 
CDV has gained great attention in the pharmaceutical 
field since its applications, already mentioned, in 
several virus infections. As a result, many researchers 
have studied different formulations, nano- and micro-
particles to improve CDV efficiency (Santoyo et al., 
2002). By using the novel radiotracer (99mTc-CDV) it 
might be possible to evaluate the release profile of CDV 
in different formulations and compare innovative release 
systems with conventional ones. Thus, this work shows 
a promising tool for assessing CDV in both in vitro and 
in vivo assays. 
CONCLUSION
Our feasibility study demonstrated that CDV can 
be successfully labeled with 99mTc, showing high and 
prolonged stability. In addition, in vitro assays showed 
a high plasma protein binding. In vivo assays confirmed 
a relatively slow half-life of CDV and its main renal 
excretion. In addition, scintigraphic imaging confirmed 
the results presented by the biodistribution studies. In 
summary, these results infer that 99mTc-CDV can be 
reliably used as a radiotracer to perform in vitro and in 
vivo studies.
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